Description

CILOSTOZ 100 MG

Indications

Cilostazol is primarily indicated for the management of intermittent claudication, a condition characterized by pain and discomfort in the legs due to inadequate blood flow during physical activity. This medication is particularly beneficial for patients with peripheral artery disease (PAD), enhancing walking distance and overall quality of life. Cilostazol may also be utilized in certain cases of ischemic heart disease and other vascular conditions, as determined by a healthcare provider.

Mechanism of Action

The pharmacological action of cilostazol is primarily attributed to its dual mechanism as a phosphodiesterase III (PDE3) inhibitor and an antiplatelet agent. By inhibiting PDE3, cilostazol increases the levels of cyclic adenosine monophosphate (cAMP) within platelets and vascular smooth muscle cells. Elevated cAMP leads to vasodilation and reduced platelet aggregation, thereby improving blood flow and reducing the risk of thrombus formation. This dual action not only alleviates symptoms of intermittent claudication but also contributes to enhanced exercise tolerance in affected patients.

Pharmacological Properties

Cilostazol is rapidly absorbed following oral administration, with peak plasma concentrations typically reached within 2 to 4 hours. It has a bioavailability of approximately 40% due to extensive first-pass metabolism in the liver. The drug is highly protein-bound (approximately 95%) and has a half-life of about 11 hours, allowing for twice-daily dosing. Cilostazol is metabolized primarily by cytochrome P450 enzymes, particularly CYP3A4, and excreted mainly through urine. Its pharmacokinetics can be influenced by various factors, including age, liver function, and co-administered medications.

Contraindications

Cilostazol is contraindicated in patients with a history of hypersensitivity to the drug or any of its components. It should not be used in individuals with heart failure of any stage, as it may exacerbate this condition. Additionally, cilostazol is contraindicated in patients with active bleeding disorders or those who are concurrently using other antiplatelet or anticoagulant medications without medical supervision. Caution is advised in patients with renal impairment, as dosage adjustments may be necessary.

Side Effects

The use of cilostazol may be associated with several side effects, which can vary in severity. Common adverse reactions include headache, diarrhea, dizziness, and palpitations. Some patients may experience gastrointestinal disturbances, such as nausea or abdominal pain. Rare but serious side effects may include tachycardia, peripheral edema, and thrombocytopenia. Patients should be monitored for any unusual symptoms, and healthcare providers should be consulted if severe or persistent side effects occur.

Dosage and Administration

The typical recommended dosage of cilostazol for the treatment of intermittent claudication is 100 mg, administered orally twice daily, approximately 30 minutes before meals or 2 hours after meals to enhance absorption. It is essential to adhere to the prescribed dosage regimen for optimal therapeutic outcomes. In patients with renal impairment or those taking medications that may interact with cilostazol, dosage adjustments may be necessary. Treatment should be periodically evaluated by a healthcare provider to assess efficacy and tolerability.

Interactions

Cilostazol may interact with several medications, potentially altering its efficacy or increasing the risk of adverse effects. Co-administration with strong CYP3A4 inhibitors, such as ketoconazole or erythromycin, can significantly increase cilostazol plasma concentrations, necessitating dose adjustments. Conversely, the use of CYP3A4 inducers, such as rifampicin, may reduce cilostazol levels and efficacy. Additionally, concurrent use with other antiplatelet or anticoagulant agents may increase the risk of bleeding. Patients should inform their healthcare provider of all medications they are taking to avoid potential interactions.

Precautions

Prior to initiating cilostazol therapy, a thorough medical history and assessment should be conducted. Caution is advised in patients with a history of cardiovascular disease, as cilostazol may cause an increase in heart rate and blood pressure. Regular monitoring of blood pressure and heart rate is recommended during treatment. Patients with hepatic impairment should use cilostazol with caution, as liver function can affect drug metabolism. Additionally, cilostazol should be used with caution in elderly patients, who may be more susceptible to side effects.

Clinical Studies

Numerous clinical studies have evaluated the efficacy and safety of cilostazol in patients with intermittent claudication. In a randomized, double-blind, placebo-controlled trial, cilostazol significantly improved walking distance and reduced claudication symptoms compared to placebo. Other studies have demonstrated that cilostazol not only enhances exercise performance but also improves quality of life measures in patients with PAD. Long-term studies indicate that cilostazol is generally well-tolerated, with a favorable benefit-risk profile. Ongoing research continues to explore the potential applications of cilostazol in other vascular conditions.

Conclusion

Cilostazol 100 mg is an effective therapeutic option for managing intermittent claudication in patients with peripheral artery disease. Its unique mechanism of action, combined with its favorable pharmacological properties, makes it a valuable addition to the treatment arsenal for this condition. However, it is essential for patients to be aware of potential side effects, contraindications, and drug interactions. Regular follow-up with healthcare providers is crucial to ensure optimal treatment outcomes and to adjust therapy as needed.